These observations indicated that PPARβ/δ agonists might have therapeutic usefulness in metabolic syndrome by increasing fatty acid consumption in skeletal muscle and reducing obesity. This evidence concerns the gene PPARD and obesity due to melanocortin 4 receptor deficiency.